Storage and handling
Store at controlled room temperature (25ºC), with excursions permitted from 15 - 30ºC (59 - 86ºF). After reconstitution, store under refrigeration.
Store at controlled room temperature (25ºC), with excursions permitted from 15 - 30ºC (59 - 86ºF). After reconstitution, store under refrigeration.
Ampicillin for injectable suspension, veterinary is a broad-spectrum penicillin which has bactericidal activity against a wide range of common gram-positive and gram-negative bacteria.
Each 25 g vial contains: 25 g ampicillin activity as ampicillin trihydrate, 90 mg methylparaben (as preservative), 10 mg propylparaben (as preservative), 200 mg lecithin, 500 mg povidone, 200 mg sodium chloride, 600 mg sodium citrate anhydrous.
The antimicrobial action of ampicillin is bactericidal, and only a small percentage of the antibiotic is serum-bound. Peak serum levels in dogs and cats are reached approximately one-half hour following subcutaneous or intramuscular injection, and in cattle 1 hour to 2 hours following intramuscular injection.
In vitro studies have demonstrated sensitivity of the following organisms to ampicillin: gram-positive bacteria - alpha- and beta-hemolytic streptococci, staphylococci (non-penicillinase-producing), Bacillus anthracis and most strains of enterococci and clostridia; gram-negative bacteria - Proteus mirabilis, E. coli and many strains of Salmonella and Pasteurella multocida.
The drug does not resist destruction by penicillinase and, hence, is not effective against strains of staphylococci resistant to penicillin G. Susceptibility tests should be conducted to estimate the in vitro susceptibility of bacterial isolates to ampicillin.
Ampicillin for injectable suspension has proved effective in the treatment of many infections previously beyond the spectrum of penicillin therapy. This drug is particularly indicated in the treatment of the following infections caused by susceptible strains of organisms:
Dogs and Cats - Respiratory Tract Infections: Upper respiratory infections, tonsillitis and bronchopneumonia due to hemolytic streptococci, Staphylococcus aureus, Escherichia coli, Proteus mirabilis and Pasteurella spp.
Urinary Tract Infections due to Proteus mirabilis, Escherichia coli, Staphylococcus spp., hemolytic streptococci and Enterococcus spp.
Gastrointestinal Infections due to Enterococcus spp., Staphylococcus spp. and Escherichia coli.
Skin, Soft Tissue and Post-Surgical Infections: Abscesses, pustular dermatitis, cellulitis and infections of the anal gland, due to Escherichia coli, Proteus mirabilis, hemolytic streptococci, Staphylococcus spp. and Pasteurella spp.
Cattle and Calves Including Non-Ruminating (Veal Calves) - Respiratory Tract Infections: Bacterial pneumonia (shipping fever, calf pneumonia and bovine pneumonia) caused by Aerobacter spp., Klebsiella spp., Staphylococcus spp., Streptococcus spp., Pasteurella multocida and E. coli susceptible to ampicillin trihydrate.
A history of allergic reactions to penicillin, cephalosporins or their analogues should be considered a contraindication for the use of this agent.
Because it is a derivative of 6-aminopenicillanic acid, ampicillin for injectable suspension has the potential for producing allergic reactions. If they should occur, ampicillin for injectable suspension should be discontinued and the subject treated with the usual agents (antihistamines, pressor amines, corticosteroids).
DO NOT TREAT CATTLE FOR MORE THAN 7 DAYS.
MILK FROM TREATED COWS MUST NOT BE USED FOR FOOD DURING TREATMENT, AND FOR 48 HOURS (4 MILKINGS) AFTER THE LAST TREATMENT.
CATTLE MUST NOT BE SLAUGHTERED FOR FOOD DURING TREATMENT, AND FOR 144 HOURS (6 DAYS) AFTER THE LAST TREATMENT.
The dosage of ampicillin for injectable suspension will vary according to the animal being treated, the severity of the infection and the animal’s response.
Dogs and Cats - The recommended dose for dogs or cats is 3 mg/lb of body weight administered twice daily by subcutaneous or intramuscular injection.
Cattle and Calves Including Non-Ruminating (Veal Calves) - From 2 mg to 5 mg/lb of body weight once daily by intramuscular injection. Do not treat for more than 7 days.
In all species, 3 days treatment is usually adequate, but treatment should be continued for 48 to 72 hours after the animal has become afebrile or asymptomatic.
The multi-dose dry-filled vials should be reconstituted to the desired concentration by adding the required amount of Sterile Water for Injection, USP, according to label directions. SHAKE WELL.
After reconstitution this product is stable for 3 months under refrigeration and will be white to pale yellow in color.
At the time of reconstitution the vial should be dated and the concentration noted on the label.
Federal law restricts this drug to use by or on the order of a licensed veterinarian.
Store at controlled room temperature (25ºC), with excursions permitted from 15 - 30ºC (59 - 86ºF). After reconstitution, store under refrigeration.
Ampicillin for injectable suspension, veterinary is supplied in vials containing 25 grams ampicillin activity as ampicillin trihydrate.
Manufactured by:
G.C. Hanford Manufacturing Co., Syracuse, NY 13201

NDC 10515-946-25 Hanford's U.S. Vet Sterile Ampicillin for Injectable Suspension, Veterinary, Equivalent to 25 g Ampicillin. Caution: Federal Law restricts this drug to use by or on the order of a licensed veterinarian. ANADA 200-180, Approved by FDA. Each vial contains: 25 g ampicillin activity as ampicillin trihydrate, 90 mg methylparaben (as preservative), 10 mg propylparaben (as preservative), 200 mg lecithin, 500 mg povidone, 200 mg sodium chloride, 600 mg sodium citrate anhydrous.
After reconstitution, this product is stable for 3 months under refrigeration. SHAKE WELL. Date Reconstituted__________ / ________mg/mL READ INNER PANEL. Dosage: Dogs and Cats - 3 mg/lb of body weight twice daily by subcutaneous or intramuscular injection. Cattle and Calves Including Non-Ruminating (Veal Calves) - From 2 mg to 5 mg/lb of body weight once daily by intramuscular injection. Do not treat for more than 7 days. See inner panel for additional dosage recommendations. Residue Warnings: Do not treat cattle for more than 7 days. Milk from treated cows must not be used for food during treatment, and for 48 hours (4 milkings) after the last treatment. Cattle must not be slaughtered for food during treatment, and for 144 hours (6 days) after the last treatment. Store at controlled room temperature (25ºC), with excursions permitted from 15 - 30ºC (59 - 86ºF). After reconstitution, store under refrigeration. Manufactured by:
G.C. Hanford Manufacturing Co. Syracuse, NY 13201 LBL16155 01 01/2017
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| AMPICILLIN TRIHYDRATE | ACTIVE INGREDIENT | HXQ6A1N7R6 | 1 | |
| AMPICILLIN | ACTIVE MOIETY | 7C782967RD | 1 | |
| ANHYDROUS TRISODIUM CITRATE | INACTIVE INGREDIENT | RS7A450LGA | 1 | |
| LECITHIN, SOYBEAN | INACTIVE INGREDIENT | 1DI56QDM62 | 1 | |
| METHYLPARABEN | INACTIVE INGREDIENT | A2I8C7HI9T | 1 | |
| POVIDONES | INACTIVE INGREDIENT | FZ989GH94E | 1 | |
| PROPYLPARABEN | INACTIVE INGREDIENT | Z8IX2SC1OH | 1 | |
| SODIUM CHLORIDE | INACTIVE INGREDIENT | 451W47IQ8X | 1 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 10515-946 | 10515-946-25 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| AMPICILLIN TRIHYDRATE | HXQ6A1N7R6 | ACTIM |
| METHYLPARABEN | A2I8C7HI9T | IACT |
| PROPYLPARABEN | Z8IX2SC1OH | IACT |
| LECITHIN, SOYBEAN | 1DI56QDM62 | IACT |
| POVIDONE, UNSPECIFIED | FZ989GH94E | IACT |
| SODIUM CHLORIDE | 451W47IQ8X | IACT |
| ANHYDROUS TRISODIUM CITRATE | RS7A450LGA | IACT |
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| ANHYDROUS TRISODIUM CITRATE | ANHYDROUS TRISODIUM CITRATE | RS7A450LGA | INJECTION, POWDER, FOR SOLUTION / INTRAVENOUS | 240 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | SUSPENSION / AURICULAR (OTIC) | 0.9 %w/v | ||
| ANHYDROUS TRISODIUM CITRATE | ANHYDROUS TRISODIUM CITRATE | RS7A450LGA | POWDER, FOR SUSPENSION / ORAL | 320 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | SUSPENSION/ DROPS / TOPICAL | 0.23 %w/v | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION / EPIDURAL | 648 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | CREAM / VAGINAL | 22 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | CAPSULE, EXTENDED RELEASE / ORAL | 41 mg | ||
| ANHYDROUS TRISODIUM CITRATE | ANHYDROUS TRISODIUM CITRATE | RS7A450LGA | INJECTION / SOFT TISSUE | 22 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | INJECTION, SUSPENSION / SUBCUTANEOUS | 0.16 %w/v | ||
| LECITHIN, SOYBEAN | SOYBEAN LECITHIN | 1DI56QDM62 | POWDER, FOR SUSPENSION / ORAL | 39 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | TABLET, ORALLY DISINTEGRATING / ORAL | 10 mg | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | CAPSULE / ORAL | 1 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | INJECTION, POWDER, FOR SOLUTION / INTRAMUSCULAR | 3.6 mg | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | DROPS / AURICULAR (OTIC) | NA | ||
| POVIDONES | POVIDONE | FZ989GH94E | SUSPENSION/ DROPS / OPHTHALMIC | 0.6 %w/v | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | POWDER / ORAL | NA | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION / INTRAVITREAL | 10 %w/v | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, SOLUTION / INTRACAUDAL | 210 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | INJECTION / PERINEURAL | 80 mg | ||
| ANHYDROUS TRISODIUM CITRATE | ANHYDROUS TRISODIUM CITRATE | RS7A450LGA | SYRUP / ORAL | 156 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION / INTRA-ARTICULAR | 26 mg | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | INJECTION, POWDER, FOR SOLUTION / INTRAVENOUS | 0.8 mg | ||
| POVIDONES | POVIDONE | FZ989GH94E | DROPS / ORAL | NA | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, SOLUTION, CONCENTRATE / INTRAMUSCULAR | 0.86 %w/v | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | CONCENTRATE / ORAL | 2.5 mg/5ml | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | SOLUTION / INTRAVENOUS | 90 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | JELLY / NASAL | 250 mg | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | SYSTEM / TOPICAL | 21 mg | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | PASTE, DENTIFRICE / DENTAL | NA | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | TABLET, DELAYED RELEASE / ORAL | 97 mg | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | INJECTION / INTRA-ARTICULAR | 0.03 %w/v | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | INJECTION / INTRAVENOUS | 95 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | SUSPENSION / INTRAMUSCULAR | 9 mg | ||
| ANHYDROUS TRISODIUM CITRATE | ANHYDROUS TRISODIUM CITRATE | RS7A450LGA | LOTION / TOPICAL | 0.08 %w/w | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | POWDER, FOR SUSPENSION / ORAL | 8 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | SUSPENSION / AURICULAR (OTIC) | NA | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | SUSPENSION/ DROPS / OPHTHALMIC | 0.01 %w/w | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | INJECTION, POWDER, FOR SOLUTION / INTRAVENOUS | 15 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | CAPSULE, EXTENDED RELEASE / ORAL | 2 mg | ||
| POVIDONES | POVIDONE | FZ989GH94E | INJECTION / INTRAMUSCULAR | 0.2 %w/v | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | FILM, SOLUBLE / BUCCAL | 1 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | DROPS / NASAL | NA | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | SOLUTION / INTRAOCULAR | 320 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | SUSPENSION / SUBCUTANEOUS | 0.16 %w/v | ||
| POVIDONES | POVIDONE | FZ989GH94E | CAPSULE / ORAL | 300 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | SOLUTION / OPHTHALMIC | 0.05 %w/w | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | SOLUTION / RECTAL | 0.13 %w/v | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | ENEMA / RECTAL | 0.02 %w/w | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | AEROSOL, FOAM / TOPICAL | 0.16 %w/w | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | SOLUTION / INTRAMUSCULAR | 0.02 %w/v | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | AEROSOL, FOAM / VAGINAL | 0.1 %w/w | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | SOLUTION / SUBCUTANEOUS | 90 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, POWDER, FOR SOLUTION / SUBCUTANEOUS | 0.68 %w/v | ||
| LECITHIN, SOYBEAN | SOYBEAN LECITHIN | 1DI56QDM62 | AEROSOL, METERED / RESPIRATORY (INHALATION) | 0.1 %w/w | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | SUSPENSION / ENDOTRACHEAL | 7.6 mg | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | SOLUTION/ DROPS / OPHTHALMIC | 0.01 %w/v | ||
| POVIDONES | POVIDONE | FZ989GH94E | TABLET, ORALLY DISINTEGRATING / ORAL | 15.03 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | INJECTION, SUSPENSION / INTRAMUSCULAR | 1 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | DROPS / OPHTHALMIC | 0.08 %w/w | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | SOLUTION / AURICULAR (OTIC) | 18 mg |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| AMPICILLIN | AMPICILLIN SODIUM | Henry Schein, Inc. | 78988f6a-a73b-4d3b-9a76-d61a748c3c16 | 2026-07-31 | Warnings, Adverse reactions | AMPICILLIN |
| Ampicillin | AMPICILLIN | REMEDYREPACK INC. | 4134cd79-c895-4e6e-b1d5-8e01c38bf2d1 | 2026-07-27 | Warnings, Adverse reactions | Ampicillin |
| ampicillin | AMPICILLIN | Sagent Pharmaceuticals | 9d2aebe8-4f04-49dd-b1e5-80b962868dc3 | 2026-07-27 | Warnings, Adverse reactions | ampicillin |
| Ampicillin | AMPICILLIN | WG Critical Care, LLC | 12b6ac82-ca74-4f88-99ea-ae4a1c419b70 | 2026-06-22 | Boxed warning, Warnings, Adverse reactions | Ampicillin |
| Ampicillin | AMPICILLIN | WG Critical Care, LLC | 38ec7b7a-9caf-45f2-88a1-0f78f089a1e4 | 2026-06-22 | Warnings, Adverse reactions | Ampicillin |
| Ampicillin | AMPICILLIN SODIUM | NorthStar Rx, LLC | 3b683547-48ac-48ca-8fd4-6866fd17be34 | 2026-06-15 | Warnings, Adverse reactions | Ampicillin |
| Ampicillin | AMPICILLIN | ONESOURCE SPECIALTY PHARMA LIMITED | 519f3ba6-606f-bfc4-e063-6294a90af884 | 2026-05-12 | Boxed warning, Warnings, Adverse reactions | Ampicillin |
| AMPICILLIN | AMPICILLIN SODIUM | Henry Schein, Inc. | 06ca924c-5f3a-4924-90f4-5ba623daaa0e | 2026-04-30 | Warnings, Adverse reactions | AMPICILLIN |
| Ampicillin | AMPICILLIN | ONESOURCE SPECIALTY PHARMA LIMITED | 519f2131-79e7-569f-e063-6394a90a2f93 | 2026-02-27 | Warnings, Adverse reactions | Ampicillin |
| AMPICILLIN | AMPICILLIN | Civica, Inc. | a194f310-a669-4d8f-8c04-ee9ca01939b1 | 2025-12-09 | Warnings, Adverse reactions | AMPICILLIN |
| AMPICILLIN | AMPICILLIN INJECTION | Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. | 302e6df7-37c5-4625-8a61-3e2f302addf2 | 2025-11-07 | Warnings, Adverse reactions | AMPICILLIN |
| Ampicillin | AMPICILLIN | Armas Pharmaceuticals Inc. | 65d94837-ca25-4728-932b-139d3bf4c716 | 2025-10-31 | Boxed warning, Warnings, Adverse reactions | Ampicillin |
| Ampicillin | AMPICILLIN SODIUM | Eugia US LLC | b7bf2897-8272-4c7d-84e9-6fbba0ea63fa | 2025-08-14 | Warnings, Adverse reactions | Ampicillin |
| Ampicillin | AMPICILLIN | Aurobindo Pharma Limited | 7f8b1ab1-73c6-4cdf-a838-7a4554c62586 | 2025-08-14 | Warnings, Adverse reactions | Ampicillin |
| Ampicillin | AMPICILLIN SODIUM | Eugia US LLC | 66146d45-0fe4-46b9-b2b1-b67c219088b7 | 2025-08-14 | Warnings, Adverse reactions | Ampicillin |
| Ampicillin | AMPICILLIN | Armas Pharmaceuticals Inc. | 34e95c91-3767-493c-8716-38e61e7c6674 | 2025-07-31 | Warnings, Adverse reactions | Ampicillin |
| Ampicillin | AMPICILLIN SODIUM | ProPharma Distribution | 364b1db9-e523-7bae-e063-6294a90a651d | 2025-07-18 | Warnings, Adverse reactions | Ampicillin |
| Ampicillin | AMPICILLIN | Sandoz Inc | 0a66c5c3-63bf-46e3-835e-26b555ab6954 | 2025-07-17 | Warnings, Adverse reactions | Ampicillin |
| Ampicillin | AMPICILLIN SODIUM | Sandoz Inc | 67dd2930-8482-4da5-b663-b751aff18c61 | 2025-05-16 | Warnings, Adverse reactions | Ampicillin |
| Ampicillin | AMPICILLIN SODIUM | Sandoz Inc | 64a04e8c-8f78-46b3-8f45-56ef225a4f74 | 2025-02-21 | Warnings, Adverse reactions | Ampicillin |
Adverse event summaries are temporarily unavailable. Other product information remains available.